Blanket Purchase Agreement V797D30042-VA797P13A0002

The key products and services being delivered under this federal contract IDV are specialized pharmaceutical and vaccine products, primarily focused on PROLASTIN-C, an alpha1-proteinase inhibitor used to treat alpha1-antitrypsin deficiency. The prime contractor, Grifols USA LLC, is a global healthcare company that specializes in the development, manufacturing, and distribution of plasma-derived medicines and other pharmaceutical supplies. The contract IDV consists of a $1.38 billion Federal...

Provention Bio Inc. was awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products by the Department of Veterans Affairs (VA) VISN 12 in July 2023. This multiple-award IDIQ contract vehicle allows federal agencies to issue task orders for these products as needed. Additionally, the VA National Acquisition Center awarded two Blanket Purchase Agreements (BPAs) to Provention Bio against this FSS contract. The...

The provided information describes a Blanket Purchase Agreement (BPA) contract vehicle awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business. The single-award BPA, valued at $50,000, enables VA facilities nationwide to order the pharmaceutical product RELYVRIO through June 2024. RELYVRIO, containing the active ingredients sodium phenylbutyrate and taurursodiol, is indicated for the...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract has a ceiling value of $3,139,060 and runs through June 2026. Under this FSS contract, the VA has issued several delivery orders and a $151,685 Blanket Purchase Agreement (BPA) to procure the drug Palynziq (pegvaliase-pqpz) from BioMarin. The delivered Palynziq is...

The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) contract to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company, to provide the medication TARPEYO. This BPA, valued at $1,750,000 and running through April 2026, designates Calliditas Therapeutics US Inc. as the sole approved supplier of TARPEYO to VA medical facilities nationwide. TARPEYO is an innovative treatment for uncontrolled protein in the urine due to primary...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Adma Biologics, Inc., a for-profit pharmaceutical company. The BPA has a ceiling value of $49,000,000 and runs through July 31, 2026. It covers the procurement of two plasma-derived pharmaceutical products: ASCENIV and BIVIGAM. Adma Biologics, which specializes in hematology-related products, also holds two Federal Supply Schedule (FSS) contracts with the Department of Veterans...

This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025. The VA Greater Los Angeles Healthcare System...

Adma Biologics, Inc., a for-profit pharmaceutical company, was awarded a Federal Supply Schedule (FSS) contract by the Department of Veterans Affairs' Veterans Integrated Service Network 12 (VISN 12). The contract, valued up to $1,549,720, is for the provision of drugs, pharmaceuticals, and hematology-related products, with a period of performance through July 14, 2029. Additionally, Adma Biologics was awarded a $49,000,000 Blanket Purchase Agreement (BPA) by the National Acquisition Center, a...

APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc., holds a multiple-award Federal Supply Schedule (FSS) contract with the U.S. Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs (FSS-61-IB). This $225,000 IDV contract has an ultimate completion date of December 14, 2026. Under this FSS contract, APL Sales I LLC has received a series of firm fixed-price delivery orders to provide the pharmaceutical product EMPAVELI 1080 MG, a complement C3 inhibitor used to treat...